Overview

Passage Bio is a genetic medicines company focused on developing transformative therapies for central nervous system disorders with limited or no approved treatment options. The company is based in Philadelphia, PA, and has a research, collaboration and license agreement with the University of Pennsylvania (Penn) and its Gene Therapy Program (GTP). The GTP conducts Investigational New Drug (IND) enabling preclinical work and Passage Bio conducts all clinical development, regulatory strategy and commercialization activities under the agreement. The company has a development portfolio of five product candidates, with lead programs in GM1 gangliosidosis and frontotemporal dementia. Passage Bio also has exploratory research programs with GTP in Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease and Temporal Lobe Epilepsy.